Kidney Cancer Weekly

January 29, 2024

Videos

Peer-to-Peer Clinical Conversations

Socioeconomic Disparities Drive Alarming Racial Gaps in Kidney Cancer Patient Survival Rates - Nirmish Singla

Nirmish Singla

Nirmish Singla presents research on socioeconomic determinants and racial disparities in renal cell carcinoma.

View

Bispecific Antibody Inhibiting PD-1 and CTLA-4 Demonstrates Effectiveness Against Advanced Kidney Cancer in Early Study - Martin Voss

Martin Voss

Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC.

View

Conference Coverage

ASCO GU 2024: Belzutifan Versus Everolimus in Participants With Previously Treated Advanced Renal Cell Carcinoma: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study

ASCO GU 2024: Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC

ASCO GU 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in Patients With Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma: Pharmacokinetics, Efficacy, and Safety Results From CheckMate 67T

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.

Urologist-level variation in the management of T1a renal cell carcinoma: A population-based cohort study.

Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Established and emerging biomarkers of immunotherapy in renal cell carcinoma.

Skeletal muscle and visceral adipose radiodensities are pre-surgical, non-invasive markers of aggressive kidney cancer.

Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma.

Retrospective Multicenter Analysis of Prognostic Risk Factors for One Year Recurrence in Patient With Renal Cell Carcinoma After Partial or Radical Nephrectomy: Results of Korean Renal Cancer Study Group (KRoCS) Database.

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.

Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
1390 Ione Pass Trail,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Kidney Cancer Weekly

Renal Cancer

Login